Post-earnings recap
Reported
Wed, Feb 11, 2026
EPS actual
$-1.38
EPS est.
$-0.89
EPS surprise
-55.23%
1-day move
-0.70%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in its stock price by 0.7%. The lack of revenue details and forward guidance may raise concerns among investors about the company's immediate outlook. Management's defensive tone suggests they are aware of the challenges ahead and are focusing on improving operations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.38 | N/A | -55.23% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over the current financial performance. They highlighted the need for strategic adjustments moving forward.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.